Development of a Prognostic Tool to Guide the Decision to Extend Adjuvant Aromatase Inhibitors for up to Ten Years in Postmenopausal Early Breast Cancer Patients

SIMPLE SUMMARY: Postmenopausal women with hormone receptor-positive early breast cancer receive adjuvant aromatase inhibitors (AIs) for five years. However, recurrences still occur at a steady rate over at least twenty years, and extending adjuvant AIs for up to ten years is an option. Our work focu...

Descripción completa

Detalles Bibliográficos
Autores principales: Moreau-Bachelard, Camille, Campion, Loïc, Robert, Marie, Kerdraon, Olivier, Renaudeau, Céline, Aumont, Maud, Classe, Jean-Marc, Campone, Mario, Frénel, Jean-Sébastien
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7763581/
https://www.ncbi.nlm.nih.gov/pubmed/33322473
http://dx.doi.org/10.3390/cancers12123725

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7763581/
https://www.ncbi.nlm.nih.gov/pubmed/33322473
http://dx.doi.org/10.3390/cancers12123725

Ejemplares similares